EICHORPublic-registry site landscape for NCT06638307, “A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer”, a Advanced Breast Cancer study sponsored by Stemline Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06638307 (registry record) |
| Study title | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer |
| Official title | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer |
| Sponsor | Stemline Therapeutics, Inc. |
| Condition(s) | Advanced Breast Cancer |
| Phase | PHASE1 |
| Listed sites | 42 |
| Site countries | United States, Spain |
Patient-friendly overview of this study: eichor.com/study/NCT06638307.
Eichor generates a preliminary site-risk snapshot for NCT06638307 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
